Detalhe da pesquisa
1.
The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
Clin Cancer Res
; 14(12): 3664-9, 2008 Jun 15.
Artigo
Inglês
| MEDLINE | ID: mdl-18559580
2.
Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
Eur J Cancer
; 44(1): 25-9, 2008 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-17845846
3.
Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).
Eur J Cancer
; 44(1): 19-24, 2008 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-17890079
4.
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Cancer Res
; 66(10): 5354-62, 2006 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-16707462
5.
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
J Clin Oncol
; 23(9): 1859-66, 2005 Mar 20.
Artigo
Inglês
| MEDLINE | ID: mdl-15699482
6.
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
Clin Cancer Res
; 11(21): 7834-40, 2005 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-16278406
7.
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Clin Cancer Res
; 11(9): 3402-9, 2005 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-15867241
8.
Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
Clin Cancer Res
; 8(1): 103-9, 2002 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-11801545
9.
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.
Mol Cancer Ther
; 1(7): 545-52, 2002 May.
Artigo
Inglês
| MEDLINE | ID: mdl-12479273
10.
Pemetrexed safety and dosing strategy.
Semin Oncol
; 29(6 Suppl 18): 24-9, 2002 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-12571807
11.
Resistance-modifying agents. 11.(1) Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to alpha1-acid glycoprotein.
J Med Chem
; 47(20): 4905-22, 2004 Sep 23.
Artigo
Inglês
| MEDLINE | ID: mdl-15369395
12.
Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.
J Med Chem
; 46(2): 210-3, 2003 Jan 16.
Artigo
Inglês
| MEDLINE | ID: mdl-12519059
13.
Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.
J Med Chem
; 47(22): 5467-81, 2004 Oct 21.
Artigo
Inglês
| MEDLINE | ID: mdl-15481984
14.
Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.
J Med Chem
; 45(23): 4961-74, 2002 Nov 07.
Artigo
Inglês
| MEDLINE | ID: mdl-12408707
15.
Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
Eur J Cancer
; 49(8): 1808-14, 2013 May.
Artigo
Inglês
| MEDLINE | ID: mdl-23428669
16.
Nucleoside transport inhibitors: structure-activity relationships for pyrimido[5,4-d]pyrimidine derivatives that potentiate pemetrexed cytotoxicity in the presence of α1-acid glycoprotein.
J Med Chem
; 54(6): 1847-59, 2011 Mar 24.
Artigo
Inglês
| MEDLINE | ID: mdl-21366300
17.
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.
Eur J Cancer
; 45(5): 741-6, 2009 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-19091546
18.
Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction.
Bioorg Med Chem Lett
; 15(5): 1515-20, 2005 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-15713419
19.
2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337.
J Natl Cancer Inst
; 95(9): 675-82, 2003 May 07.
Artigo
Inglês
| MEDLINE | ID: mdl-12734319
20.
Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.
Br J Clin Pharmacol
; 53(1): 83-91, 2002 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-11849199